Attruby (acoramidis), an approved therapy for transthyretin amyloid cardiomyopathy (ATTR-CM), may help preserve kidney function in adults with the rare heart disease, potentially lowering their risk of early cardiovascular events, according to a new analysis of clinical trial data.
“Kidney dysfunction is pervasive in this population and an independent predictor of mortality from ATTR-CM,” Jeffrey Testani, MD, the study’s first author at Yale School of Medicine, said in a press release from Bridgebio, the company that sells Attruby in the U.S. The oral therapy “appears to have a protective effect on the heart and the kidney simultaneously, with potentially meaningful implications for long-term survival and reduced cardiovascular hospitalizations.”